- Home
- DUK vs NPCE Comparison
DUK vs NPCE Comparison
Compare DUK & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$127.75
HOLD
Current Price
$15.12
Company Overview
Basic Information| Metric | DUK | NPCE |
|---|---|---|
| Founded | 1904 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3B | 514.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DUK | NPCE |
|---|---|---|
| Price | $127.75 | $15.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $133.86 | $18.33 |
| AVG Volume (30 Days) | ★ 4.8M | 156.4K |
| Earning Date | 02-10-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | ★ 10.87 | N/A |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $32,237,000,000.00 | $94,864,000.00 |
| Revenue This Year | $3.29 | $26.20 |
| Revenue Next Year | $4.13 | N/A |
| P/E Ratio | $19.95 | ★ N/A |
| Revenue Growth | 7.69 | ★ 24.08 |
| 52 Week Low | $110.51 | $7.56 |
| 52 Week High | $130.03 | $18.98 |
Technical Indicators
Market Signals| Indicator | DUK | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 38.44 |
| Support Level | $120.46 | $14.02 |
| Resistance Level | $128.09 | $15.97 |
| Average True Range (ATR) | 2.10 | 0.75 |
| MACD | 0.52 | -0.18 |
| Stochastic Oscillator | 74.15 | 23.54 |
Price Performance
Historical Comparison DUK
NPCE
About DUK Duke Energy Corporation (Holding Company)
Duke Energy is one of the largest US utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to more than 8 million customers. Its natural gas utilities serve more than 1.6 million customers.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.